AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04507022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor
Description: 2.5 mg twice daily for 5 days
Study NCT02136966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MNP + IYCN counseling + cooking demonstrations
Description: Growth monitoring and promotion sessions will take place every month at village level for all children 0-23 months of age and will serve as an entry point for all the interventions. During these sessions children under 24 months will be weighed monthly and screened for MAM and uncomplicated SAM for treatment in the community as well as complicated SAM for referral to health facility During the monthly sessions cooking demonstrations will take place in which the community Health workers will instruct the mother how to prepare a good complementary food for 6-23 months olds adding the MNP. These meals will be given to the child during the session. Mothers will be encouraged to prepare the same meal at home During the monthly sessions enhanced IYCN counseling will be given to the mothers of 6-23 months olds, using improved BCI messages developed based on the rapid assessment of practices and foods available in the community and adaptation of the WHO manual.
Study NCT03596905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide
Description: Taken orally daily for 4 weeks
Study NCT03596905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Taken orally daily for 4 weeks
Study NCT02237326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Visual Inspection with Acetic Acid
Description: Visual Inspection with Acetic Acid is the application of acetic acid to a cervix, followed by examination with a light source. It is not a new drug or device, and has been used in resource-limited settings for several decades. The purpose of this trial is to compare the two screening techniques, which had not been done previously.
Study NCT02237326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Visual Inspection with Lugol's Iodine
Description: Visual Inspection with Lugol's Iodine is the application of lugol's iodine to a woman's cervix, followed by examination with a light source with the goal of detecting precancerous lesions. Like Visual Inspection with Acetic Acid, it is not a new drug or device.
Study NCT05439044 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Anti SARS-CoV-2 Monoclonal Antibodies: casirivimab-imdevimab (Ronapreve) OR bamlanivimab-etesevimab OR tixagevimab-cilgavimab (Evusheld) OR regdanvimab OR sotrovimab (Xevudy) OR adintrevimab
Study NCT02785185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-122 Vehicle Lotion
Description: Vehicle
Study NCT02785185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-122 Vehicle Cream
Description: Vehicle
Study NCT02785185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-122 Lotion
Description: Lotion
Study NCT02785185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultravate Cream
Description: Cream
Study NCT03955835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.
Description: Self-expandable Credo® stent together with NeuroSpeed® PTA balloon catheter. Credo® and NeuroSpeed® are already CE approved products, for which within ACUTE an additional new indication shall be examined.
Study NCT01373463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed by vein every 21 days for 3 cycles
Study NCT01373463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin by vein Every 21 days for 3 cycles
Study NCT01373463 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment 5 days a week for 5-6 weeks.
Study NCT01373463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin by vein every 21 days for 3 cycles
Study NCT01373463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lobectomy
Description: Surgery
Study NCT01373463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lobectomy
Description: Surgery to remove a portion of the lung where the tumor is located.
Study NCT00833040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual sufentanil NanoTabs™ and placebo NanoTabs™
Description: During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
Study NCT04458155 — intervention group
Intervention type: DEVICE
Intervention: Siemens® Point-of-care high sensitive troponin I analyzer
Description: Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Siemens® device.
Study NCT00420485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gimatecan
Study NCT02768766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib, 100mg
Description: 100mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.
Study NCT02768766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib, 125mg
Description: 125mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.
Study NCT02768766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib, 150mg
Description: 150mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.
Study NCT02768766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib, 175mg
Description: 175mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.
Study NCT02768766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib, 200mg
Description: 200mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.
Study NCT02768766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib, 225mg
Description: 225mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.
Study NCT04443634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Adductor Canal Block
Description: It will be performed at the midthigh level, approximately halfway between the superior anterior iliac spine and the patella, a high-frequency linear ultrasound (US) transducer 5-12 MHz probe. Underneath the sartorius muscle the femoral artery was identified, with the vein just inferior and the saphenous nerve just lateral to the artery. From the lateral side of the transducer a 10-cm, 18-gauge Tuohy needle (Braun Medical, Melsungen, Germany) was inserted in plane, through the Sartorius muscle. With the tip of the Tuohy needle placed just underneath the vasto-adductor membrane and lateral to the artery and the saphenous nerve, 20 ml local anesthetic mixture will be injected to expand the adductor canal. the volume of local anesthetic will be selected according to the studied group
Study NCT04443634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Saphenous Nerve Block
Description: It will be performed at the intermuscular plane between the sartorius and the vasus medialis muscles at the lower third of the thigh.~The US probe will be positioned on the front of the lower part of the thigh immediately above the patella to see both the patella (hyperechoic curved line) and vastus medialis infront of it (closer to skin). The probe is then moved medially over the vastus medialis till we see the end of the muscle and we see an intermuscular plane between it and Sartorius muscle. A 20 guage spinal needle will be then passed in an in plane direction within the substance of vastus medialis muscle and then pass within the vastus medialis until it faces the intermuscular plane between VM muscle and Sartorius. Once the needle tip is located in close proximity to the target structures, gentle aspiration will be performed followed by 20 ml local anesthetic will be injected.
Study NCT04443634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anesthesia was induced by propofol 1-2 mg/kg fentanyle 100micg and laryngeal mask was inserted. Maintanace of anesthesia was performed by sevoflurane 2-3%.~Then the surgical procedure started. All patients had arthroscopic knee surgery( ACL repair) surgery under tourniquet control.~Immediately after end the surgical procedure, either ACB or combined ACB and saphenous nerve block distal to adductor canal were performed according to randomization.
Study NCT04443634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 20 ml
Description: 20ml bupivacaine 0.5%
Study NCT04443634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 30ml
Description: 30ml bupivacaine 0.5%
Study NCT04443634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 10ml
Description: 10ml bupivacaine 0.5%
Study NCT01067378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-led debriefing
Study NCT01067378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expert instructor debriefing
Study NCT02495701 — intervention group
Intervention type: PROCEDURE
Intervention: Hip arthroscopic surgery
Description: Hip arthroscopic surgery
Study NCT04085419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab 60 MG/ML Prefilled Syringe [Prolia]
Description: denosumab 60 mg subcutaneously every 6 months
Study NCT04085419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: zoledronic acid 5 mg intravenously once a year
Study NCT00666666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101
Description: AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.
Study NCT00666666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.
Study NCT00666666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LHRH agent
Description: An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
Study NCT03885635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarch repair
Description: Current standard of surgical repair consisting of ascending aortic replacement with open distal anastomosis at level of proximal arch under a period of hypothermic circulatory arrest . No surgical or endovascular intervention is carried out in the mid arch or descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
Study NCT03885635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extended arch repair
Description: Surgical replacement of the ascending aorta along with intervention on the arch and descending aorta. Techniques for distal aspect of extended arch technique include but are not limited to total arch replacement along with TEVAR, Frozen Elephant Trunk procedure or surgical proximal arch replacement with bare metal stents in arch and descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
Study NCT01758809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-emptive bupivacaine wound infiltration
Description: Pre-emptive bupivacaine wound infiltration
Study NCT01758809 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: intravenous patient controlled analgesia
Description: postoperative pain control with intravenous patient controlled analgesia
Study NCT03347123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Phase 1: Epacadostat at the protocol-defined dose twice daily. Phase 2: Epacadostat at the recommended dose from Phase 1.
Study NCT03347123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab at the protocol-specified dose and schedule.
Study NCT03347123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab at the protocol-specified dose and schedule.
Study NCT03347123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Lirilumab at the protocol-specified dose and schedule.
Study NCT03935958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Patients will receive curcumin 2000 mg a day, for 12 months
Study NCT03935958 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months
Study NCT01046981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumescent Antibiotic Delivery of cefazolin with or without metronidazole
Description: TAD of cefazolin with or without metronidazole followed by sequential serum and interstitial fluid samples over 14 to 24 hours for antibiotic concentrations
Study NCT01046981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Antibiotic Delivery
Description: Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum sampling for antibiotic concentration of subsequent 12 to 24 hours.
Study NCT01161186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel, gemcitabine, capecitabine
Description: {nab-paclitaxel: Intravenous, 100 to 150 mg/m2 over 30 minutes once per cycle.} {gemcitabine: Intravenous, 750 to 1000 mg/m2 at 10mg/m2/minute once per cycle.} {capecitabine: oral, 500 to 1000 mg/m2 b.i.d. 7 days per cycle}
Study NCT03929172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVLP-HPV
Description: 20μg/injection formulated in a ready to use solution containing 100mM sodium citrate, 2.5 mM MgCl2, 0.001% pluronic F-68, pH 6.0 for i.m. injection as 0.5 mL per injection.
Study NCT03929172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL 100 mM Sodium Citrate, 2.5 mM MgCl2, 0.001% Pluronic F-68, pH 6 for i.m. injection as 0.5 mL per injection.
Study NCT04569877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim nebuliser solution
Description: 300μg molgramostim nebuliser solution nebulised seven times within 7 days via rapid nebuliser system
Study NCT04569877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nebuliser solution
Description: Placebo nebulised seven times within 7 days via rapid nebuliser system
Study NCT01102088 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions.
Study NCT02718521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate
Description: Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration conbined with isosorbide dinitrate in all patients 6 hours before angiography and 12 hours after angiography
Study NCT01480219 — intervention group
Intervention type: DRUG
Intervention: voriconazole (Vfend)
Description: Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
Study NCT01480219 — intervention group
Intervention type: OTHER
Intervention: no voriconazole (Vfend)
Description: Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
Study NCT02718521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate
Description: Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration conbined with isosorbide dinitrate in all patients 6 hours before angiography and 12 hours after angiography
Study NCT02718521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque
Description: All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
Study NCT02718521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visipaque
Description: All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
Study NCT02718521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride ﬂuid administration
Study NCT02718521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride ﬂuid administration
Study NCT02718521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosorbide dinitrate
Study NCT00917930 — intervention group
Intervention type: BEHAVIORAL
Intervention: physical training
Description: intensive cardiac rehabilitation program
Study NCT02316028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: administration of decitabine by hepatic arterial infusion~* Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~* Proposed dose levels:~  1. 10 mg/m2 per course~ 2. 15 mg/m2 per course~ 3. 20 mg/m2 per course
Study NCT04636281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active and passive static stretching exercises
Description: Different group of muscles will be stretched one by one, tricep brachii, bicep brachii, wrist exentsor etc
Study NCT03546985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: episil®
Description: Firmly press the pump and apply the stream of liquid to the oral cavity 3 times (a total volume of 0.45 mL approximately). Distribute to affected areas in the mouth, for example by using the tongue. Wait for 5 minutes for the protective film to form.
Study NCT03546985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kang Su
Description: Gently pour 5 mL of rinse into the mouth, keep the rinse staying in the oral cavity for at least 1 minute, and spilt out the liquid.
Study NCT04061122 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: airway epithelial smear test
Description: all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture
Study NCT00530413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Description: Phenobarbital will be given based on weight range
Study NCT00530413 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study NCT01062750 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: adipose tissue derived stromal cells dosage
Description: single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization